Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human BIRC2 Antibodies:
anti-Rat (Rattus) BIRC2 Antibodies:
anti-Mouse (Murine) BIRC2 Antibodies:
Go to our pre-filtered search.
Dog (Canine) Polyclonal BIRC2 Primary Antibody for IHC (fro), IHC (p) - ABIN4298716
Chui, Ma, Li, Xu, Yao, Lin, Chan, Lee: Anti-apoptotic protein BRE/BRCC45 attenuates apoptosis through maintaining the expression of caspase inhibitor XIAP in mouse Lewis lung carcinoma D122 cells. in Apoptosis : an international journal on programmed cell death 2014
Dog (Canine) Polyclonal BIRC2 Primary Antibody for IHC (fro), IHC (p) - ABIN537405
Lin, Chang, Ho, Huang: Ischemic preconditioning reduces neurovascular damage after hypoxia-ischemia via the cellular inhibitor of apoptosis 1 in neonatal brain. in Stroke; a journal of cerebral circulation 2012
We further identified this underlying mechanism also involved a PPARgamma (show PPARG Antibodies)-induced ANXA1 (show ANXA1 Antibodies)-dependent autoubiquitination of cIAP1, the direct E3 ligase of RIP1 (show UQCRFS1 Antibodies), shifting cIAP1 toward proteosomal degradation..our study provides first insight for the suitability of using drug-induced expression of ANXA1 (show ANXA1 Antibodies) as a new player in RIP1 (show UQCRFS1 Antibodies)-induced death machinery in triple-negative breast cancer
NAIP (show NAIP Antibodies) expression is most abundant in M2 macrophages, while cIAP1 and cIAP2 (show BIRC3 Antibodies) show an inverse pattern of expression in polarized cells, cIAP2 (show BIRC3 Antibodies) is preferentially expressed in M1-macrophages and cIAP1 in M2-macrophages. IAP (show ALPI Antibodies) antagonist treatment of resting M0 macrophages preceding polarization stimulation, induced upregulation of NAIP (show NAIP Antibodies) in M2 and downregulation of cIAP1 in M1 and M2 but an induction of cIAP2 (show BIRC3 Antibodies) in M1 macrophages.
we conclude that DMBT1 (show DMBT1 Antibodies) by binding with CRNDE and c-IAP1 associated with PI3K (show PIK3CA Antibodies)-AKT (show AKT1 Antibodies) pathway is crucial for GBC carcinogenesis, and targeting this pathway may be pivotal in the treatment of GBC.
These results reveal an additional level of regulation of the stability and the activity of E2F1 (show E2F1 Antibodies) by a non-degradative K63-poly-ubiquitination and uncover a novel function for the E3-ubiquitin ligase (show MUL1 Antibodies) cIAP1.
High cIAP1 expression is associated with colorectal cancer.
the cytoplasmic retinoic acid receptor gamma (show RARG Antibodies) (RARgamma) controls receptor-interacting protein (show RIPK1 Antibodies) kinase (show CDK7 Antibodies) 1 (RIP1 (show UQCRFS1 Antibodies))-initiated cell death when cellular inhibitor of apoptosis (cIAP) activity is blocked.
High cIAP1 expression is associated with Lung Tumorigenesis.
These data suggest that molluscum contagiosum virus MC159 competitively binds to NEMO (show IKBKG Antibodies) to prevent cIAP1-induced NEMO (show IKBKG Antibodies) polyubiquitination.
The baseline tumor necrosis factor (show TNF Antibodies) tumor (TNFalpha (show TNF Antibodies)) expression correlates with the sensitivity to Inhibitors of apoptosis proteins (IAPs) antagonist T-3256336.
cIAP1-induced mitophagy led to dysfunctional mitochondria that resulted in abrogation of mitochondrial oxygen consumption rate along with the decrease in ATP levels. The ubiquitination of cIAP1 was found to be the critical regulator of mitophagy.
Drugs targeting XIAP (show XIAP Antibodies) and cIAP1/2 may be effective for osteosarcoma patients whose tumors express abundant RIPK1 (show RIPK1 Antibodies) and contain high levels of TNFalpha (show TNF Antibodies).
Results identify IGF2BP1 (show B4GALNT2 Antibodies) as a critical translational regulator of cIAP1-mediated apoptotic resistance in rhabdomyosarcoma.
Identify xIAP (show XIAP Antibodies) and cIAP1 as molecular targets of ceramide and show ceramide analog LCL85 is an effective sensitizer in overcoming resistance of metastatic colon and breast cancers to apoptosis induction to suppress metastasis in vivo.
NFATc1 (show NFATC1 Antibodies) mRNA expression is negatively regulated by inhibitor of apoptosis protein 2 during osteoclastogenesis.
cIAP1 expression protects macrophages from Rip1 (show RALBP1 Antibodies)-dependent necroptotic cell death and facilitates pathogen control.
cIAP1 plays a critical role in beta-cell survival under endoplasmic reticulum stress: by promoting ubiquitination and degradation of C/EBP homologous protein (CHOP (show DDIT3 Antibodies))
Deficiency in cIAP1 (encoded by Birc2) or cIAP2 (Birc3 (show BIRC3 Antibodies)) impaired caspase-1 (show CASP1 Antibodies) activation after spontaneous or agonist-induced inflammasome assembly.
These findings identify critical role of cIAP1, cIAP2 (show BIRC3 Antibodies) and Yap1 (show YAP1 Antibodies) co-expression in mammary carcinogenesis
Murine IAP1 (show BIRC3 Antibodies) is alternatively spliced at intron 6-7, generating protein isoforms with significantly different functional properties compared to the full-length mIAP1, in vitro.
Data show that apoptosis caused by an IAP (show ALPI Antibodies) antagonist compound is blocked by the caspase 8 (show CASP8 Antibodies) inhibitor crmA and that IAP (show ALPI Antibodies) antagonists activate NF-kappaB (show NFKB1 Antibodies) signaling via inhibtion of cIAP1.
The protein encoded by this gene is a member of a family of proteins that inhibits apoptosis by binding to tumor necrosis factor receptor-associated factors TRAF1 and TRAF2, probably by interfering with activation of ICE-like proteases. This encoded protein inhibits apoptosis induced by serum deprivation and menadione, a potent inducer of free radicals. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
IAP homolog B
, NFR2-TRAF signalling complex protein
, RING finger protein 48
, TNFR2-TRAF-signaling complex protein 2
, apoptosis inhibitor 1
, baculoviral IAP repeat-containing 2
, baculoviral IAP repeat-containing protein 2
, inhibitor of apoptosis protein 2
, apoptosis inhibitor 2
, inhibitor of apoptosis protein
, IAP homolog
, inhibitor of T-cell apoptosis protein
, inhibitor of apoptosis 1
, baculoviral IAP repeat-containing 3
, inhibitor of apoptosis protein-1
, inhibitor of apoptosis protein 1
, bZ1P14.6.2 (baculoviral IAP repeat-containing 3 )
, baculoviral IAP repeat containing 2 L homeolog